Aller au contenu principal
Accès ouvert déclaré 2025 article

Salvage Surgery Following Systemic Therapy in Initially Unresectable Non‐Small Cell Lung Cancer

1Citations signalées — pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

BACKGROUND: This study evaluated the safety, long-term survival, and prognostic factors associated with salvage pulmonary surgery following systemic therapy for initially unresectable non-small cell lung cancer (NSCLC). METHODS: Between 2014 and 2024, this single-center retrospective review identified 32 patients (median age: 61.0 years) with NSCLC initially considered unresectable who subsequently underwent curative-intent pulmonary resection after chemotherapy, targeted therapy, and/or immunotherapy. The primary endpoint was overall survival (OS); secondary endpoints included recurrence-free survival (RFS), major morbidity (Clavien-Dindo grade ≥ IIIa), and R0 resection rate. The Kaplan-Meier method and log-rank test were employed. RESULTS: Reasons for unresectability at initial diagnosis were distant metastasis (n = 20; 62.5%), N3 nodal disease (n = 6; 18.8%), bulky N2 nodal disease (n = 3; 9.4%), and tumor or nodal extension requiring pneumonectomy (n = 3; 9.4%). Overall, 65.6% patients underwent lobectomy, with R0 resection achieved in 81.3% and pathological complete or major response observed in 15.6%. Overall complication and major morbidity rates were 12.5% and 3.1%, respectively; no 90-day mortality was observed. After a median follow-up of 40.1 months, median OS was not reached, whereas median RFS was 49.9 months; 5-year OS and RFS were 75.0% (95% CI 51.6-88.3) and 46.3% (95% CI 26.3-64.2), respectively. Notably, adenocarcinoma histology was significantly more prevalent in the good-prognosis group (88.9% vs. 35.7%, p = 0.003). CONCLUSIONS: Salvage pulmonary surgery following systemic therapy is safe, yielding a 5-year OS rate of 75% in carefully selected patients with advanced NSCLC. Prevalent adenocarcinoma histology in the good-prognosis cohort is associated with superior outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Salvage Surgery Following Systemic Therapy in Initially Unresectable Non‐Small Cell Lung Cancer
Date Crossref
01/12/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsLung Cancer Research Studies

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.